Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome
Purpose: To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation. Materials and methods: Sevent...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-04-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223001567 |
| _version_ | 1797894715617574912 |
|---|---|
| author | Raúl Martínez-Castillo Carmen González-Gallardo José I. Muñoz-Ávila Pilar Font Marta Villalba-González Indira Stoikow Ignacio Fernández-Choquet de Isla Francisco Pugliese Roberto Anaya-Alaminos José L. García-Serrano Francisco Hermoso-Fernández Fabio Contieri José E. Muñoz-de-Escalona-Rojas Lorena Pérez-Fajardo Mario Blanco-Blanco Yolanda Jiménez-Gómez Miguel González-Andrades |
| author_facet | Raúl Martínez-Castillo Carmen González-Gallardo José I. Muñoz-Ávila Pilar Font Marta Villalba-González Indira Stoikow Ignacio Fernández-Choquet de Isla Francisco Pugliese Roberto Anaya-Alaminos José L. García-Serrano Francisco Hermoso-Fernández Fabio Contieri José E. Muñoz-de-Escalona-Rojas Lorena Pérez-Fajardo Mario Blanco-Blanco Yolanda Jiménez-Gómez Miguel González-Andrades |
| author_sort | Raúl Martínez-Castillo |
| collection | DOAJ |
| description | Purpose: To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation. Materials and methods: Seventy-three nAMD patients (73 eyes) treated with anti-VEGF agents for 12 months using the pro re nata regimen were included in this retrospective longitudinal study. Patients were split into 3 groups according to the time from diagnosis to first anti-VEGF injection: < 48 h (group 1); 48 h-7 days (group 2); > 7 days (group 3). Decimal best-corrected visual acuity (VA) and macular thickness (MT) were recorded at baseline and 1–2-, 3–4-, 6- and 12-month later. Furthermore, age, gender as well as the applied treatment and number of injections after 12 months of treatment were also registered and compared. Results: Long-term effect of the treatment demonstrated enhanced VA in group 1 patients compared with the rest of groups after 1–2-, 6-, and 12-month follow-up (P < 0.05). Positive effects of early treatment were additionally corroborated by the augmented percentage of patients with normal VA in the group 1 respect to the rest of groups over studied time points (P < 0.05). Moreover, the VA gain in nAMD at group 1 was obtained with a mean of 3.7 intravitreal injections over 1-year follow-up period. Regarding MT, non-significant difference was observed among groups. Conclusions: An early initial treatment with VEGF inhibitors is critical to achieve the best functional benefits of this therapy in new-onset nAMD patients. |
| first_indexed | 2024-04-10T07:13:43Z |
| format | Article |
| id | doaj.art-21bcecac66084e0eb5ecba471bd36ba2 |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-10T07:13:43Z |
| publishDate | 2023-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-21bcecac66084e0eb5ecba471bd36ba22023-02-26T04:26:36ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-04-01160114368Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcomeRaúl Martínez-Castillo0Carmen González-Gallardo1José I. Muñoz-Ávila2Pilar Font3Marta Villalba-González4Indira Stoikow5Ignacio Fernández-Choquet de Isla6Francisco Pugliese7Roberto Anaya-Alaminos8José L. García-Serrano9Francisco Hermoso-Fernández10Fabio Contieri11José E. Muñoz-de-Escalona-Rojas12Lorena Pérez-Fajardo13Mario Blanco-Blanco14Yolanda Jiménez-Gómez15Miguel González-Andrades16Department of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Cordoba, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainDepartment of Ophthalmology, San Cecilio University Hospital, 18016 Granada, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, SpainMaimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain; Correspondence to: University of Cordoba and Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Avenue Menéndez Pidal, s/n, 14004 Cordoba, Spain.Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Cordoba, Spain; Department of Medical and Surgical Sciences, School of Medicine, University of Cordoba, 14004 Cordoba, Spain; Department of Ophthalmology, Reina Sofia University Hospital, 14004 Cordoba, Spain; Correspondence to: University of Cordoba and Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Avenue Menéndez Pidal, s/n, 14004 Cordoba, Spain.Purpose: To evaluate long-term visual and anatomical outcomes in neovascular age-related macular degeneration (nAMD) patients treated with anti-vascular endothelial growth factor (VEGF) agents depending on the time delay from confirmed diagnosis to treatment initiation. Materials and methods: Seventy-three nAMD patients (73 eyes) treated with anti-VEGF agents for 12 months using the pro re nata regimen were included in this retrospective longitudinal study. Patients were split into 3 groups according to the time from diagnosis to first anti-VEGF injection: < 48 h (group 1); 48 h-7 days (group 2); > 7 days (group 3). Decimal best-corrected visual acuity (VA) and macular thickness (MT) were recorded at baseline and 1–2-, 3–4-, 6- and 12-month later. Furthermore, age, gender as well as the applied treatment and number of injections after 12 months of treatment were also registered and compared. Results: Long-term effect of the treatment demonstrated enhanced VA in group 1 patients compared with the rest of groups after 1–2-, 6-, and 12-month follow-up (P < 0.05). Positive effects of early treatment were additionally corroborated by the augmented percentage of patients with normal VA in the group 1 respect to the rest of groups over studied time points (P < 0.05). Moreover, the VA gain in nAMD at group 1 was obtained with a mean of 3.7 intravitreal injections over 1-year follow-up period. Regarding MT, non-significant difference was observed among groups. Conclusions: An early initial treatment with VEGF inhibitors is critical to achieve the best functional benefits of this therapy in new-onset nAMD patients.http://www.sciencedirect.com/science/article/pii/S0753332223001567Neovascular age-related macular degenerationVisual acuityMacular thicknessIntravitreal injectionsAnti-vascular endothelial growth factor therapy |
| spellingShingle | Raúl Martínez-Castillo Carmen González-Gallardo José I. Muñoz-Ávila Pilar Font Marta Villalba-González Indira Stoikow Ignacio Fernández-Choquet de Isla Francisco Pugliese Roberto Anaya-Alaminos José L. García-Serrano Francisco Hermoso-Fernández Fabio Contieri José E. Muñoz-de-Escalona-Rojas Lorena Pérez-Fajardo Mario Blanco-Blanco Yolanda Jiménez-Gómez Miguel González-Andrades Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome Biomedicine & Pharmacotherapy Neovascular age-related macular degeneration Visual acuity Macular thickness Intravitreal injections Anti-vascular endothelial growth factor therapy |
| title | Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome |
| title_full | Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome |
| title_fullStr | Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome |
| title_full_unstemmed | Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome |
| title_short | Treatment of neovascular age-related macular degeneration within 48 h from diagnosis improves long-term functional outcome |
| title_sort | treatment of neovascular age related macular degeneration within 48 h from diagnosis improves long term functional outcome |
| topic | Neovascular age-related macular degeneration Visual acuity Macular thickness Intravitreal injections Anti-vascular endothelial growth factor therapy |
| url | http://www.sciencedirect.com/science/article/pii/S0753332223001567 |
| work_keys_str_mv | AT raulmartinezcastillo treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT carmengonzalezgallardo treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT joseimunozavila treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT pilarfont treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT martavillalbagonzalez treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT indirastoikow treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT ignaciofernandezchoquetdeisla treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT franciscopugliese treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT robertoanayaalaminos treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT joselgarciaserrano treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT franciscohermosofernandez treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT fabiocontieri treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT joseemunozdeescalonarojas treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT lorenaperezfajardo treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT marioblancoblanco treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT yolandajimenezgomez treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome AT miguelgonzalezandrades treatmentofneovascularagerelatedmaculardegenerationwithin48hfromdiagnosisimproveslongtermfunctionaloutcome |